# Bacillus Calmette-Guérin-Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drugs and Biological Products for Treatment : Draft Guidance for Industry - FDA Guidance Document

Source: https://www.keypedia.com/guidances/guidance-document/bacillus-calmette-guerin-unresponsive-nonmuscle-invasive-bladder-cancer-developing-drugs-and-biological-products-for-treatment-draft-guidance-for-industry/3fae8291-7235-49ce-9d2d-1d17d90d4656

> FDA guidance document: Bacillus Calmette-Guérin-Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drugs and Biological Products for Treatment : Draft Guidance for Industry. Issue date: August 08, 2024. Get complete insights and analysis.

---

## Details

- Title: Bacillus Calmette-Guérin-Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drugs and Biological Products for Treatment : Draft Guidance for Industry
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2024-08-08
- Last Changed: 2024-08-09
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2018-D-0342 ">FDA-2018-D-0342 </a>

## Related Documents

- [Real-World Evidence: Considerations Regarding Non-Interventional Studies for Drug and Biological Products](https://www.keypedia.com/guidances/guidance-document/real-world-evidence-considerations-regarding-non-interventional-studies-for-drug-and-biological-products/48325e39-b445-4a53-8cc0-7483dcf3e352)
- [Acute Myeloid Leukemia:  Developing Drugs and Biological Products for Treatment: Draft Guidance for Industry](https://www.keypedia.com/guidances/guidance-document/acute-myeloid-leukemia-developing-drugs-and-biological-products-for-treatment-draft-guidance-for-industry/8143a606-18fc-488c-b3ab-4c23bdcd999a)
- [Biomarker Qualification: Evidentiary Framework: Draft Guidance for Industry and FDA Staff](https://www.keypedia.com/guidances/guidance-document/biomarker-qualification-evidentiary-framework-draft-guidance-for-industry-and-fda-staff/c198796d-4230-4499-a6ee-2f84eed424c9)